Publication
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (20)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 20
- cancerAcute Lymphoblastic Leukemiacivic_curation1.00
- cancerChronic Myeloid Leukemia, BCR-ABL1 Positivecivic_curation1.00
- drugDasatinibcivic_curation1.00
- drugImatinib Mesylatecivic_curation1.00
- geneABL1civic_curation1.00
- variantABL1 A397Pcivic_curation1.00
- variantABL1 E255Kcivic_curation1.00
- variantABL1 E355Gcivic_curation1.00
- variantABL1 E459Kcivic_curation1.00
- variantABL1 F317Lcivic_curation1.00
- variantABL1 F359Ccivic_curation1.00
- variantABL1 F359Vcivic_curation1.00
- variantABL1 Fusioncivic_curation1.00
- variantABL1 G250Ecivic_curation1.00
- variantABL1 L248Vcivic_curation1.00
- variantABL1 M244Vcivic_curation1.00
- variantABL1 M351Tcivic_curation1.00
- variantABL1 T315Icivic_curation1.00
- variantABL1 V379Icivic_curation1.00
- variantABL1 Y253Hcivic_curation1.00
Curated evidence
Evidence citing this paper (31)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 17264298
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL1 T315I + ABL1 Fusion2 | ||||||||
| Dasatinib | Acute Lymphoblastic Leukemia | Predictive | C | Supports Resistance | 2 | accepted | EID4376In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7038In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 5 had T315I mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 E255K1 | ||||||||
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | rejected | EID7032In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had E255K mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 V379I1 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4704In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 A397P + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4710In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7034In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had A397P mutations. Both patients with A397P mutation achieved major hematologic response, and one also had major cytog… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 E255K + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Reduced Sensitivity | 1 | accepted | EID4352In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7039In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had E255K mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 E255V + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 1 | submitted | EID4446In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 2 | submitted | EID7245In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had E255V mutations. PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 E355G + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4402In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7036In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had E355G mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 E459K + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 1 | accepted | EID7031In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7046In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had E459K mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 F317L + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Reduced Sensitivity | 1 | accepted | EID7030In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7045In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had F317L mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 F359C + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 2 | accepted | EID4481In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7035In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 2 had F359C mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 F359V + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Reduced Sensitivity | 1 | accepted | EID3817In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7043In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 7 had F359V mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 G250E + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Reduced Sensitivity | 1 | accepted | EID4318In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | B | Supports Resistance | 1 | accepted | EID7041In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 9 had G250E mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 L248V + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 1 | accepted | EID7029In this phase II multinational study, 60 imatinib-resistantpatients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achie… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7044In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 3 had L248V mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 M244V + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4304In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achi… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7042In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 5 had M244V mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 M351T + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Reduced Sensitivity | 1 | accepted | EID4397In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 1 | accepted | EID7037In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had M351T mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 V379I + ABL1 Fusion1 | ||||||||
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Supports Resistance | 3 | accepted | EID7033In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 4 had V379I mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| ABL1 Y253H + ABL1 Fusion2 | ||||||||
| Dasatinib | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | C | Does Not Support Resistance | 1 | accepted | EID4334In this phase II multinational study, 60 imatinib-resistant patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. 44 (73%) of 60 BCR-ABL mutant patients achi… (full text at CIViC) PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |
| Imatinib Mesylate | Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS | Predictive | B | Supports Resistance | 1 | accepted | EID7040In a phase II study of 60 imatinib-resistant patients with BCR-ABL mutations, 6 had Y253H mutations PMID 17264298 · Guilhot et al., 2007 · Open in CIViC | civic |